FDx Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

FDx Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,508	Closed	-$627K	–	860
2023 Q1	$627K	Hold	5,508	–	–	0.03%	378
2022 Q4	$627K	Sell	5,508 -394	-7%	-$32.7K	0.03%	378
2022 Q3	$365K	Sell	5,902 -10,097	-63%	-$706K	0.02%	488
2022 Q2	$1.28M	Buy	15,999 +705	+5%	+$66.8K	0.05%	275
2022 Q1	$1.61M	Sell	15,294 -837	-5%	-$81.6K	0.05%	244
2021 Q4	$1.74M	Buy	16,131 +622	+4%	+$67.9K	0.05%	248
2021 Q3	$1.7M	Sell	15,509 -245	-2%	-$25.4K	0.05%	236
2021 Q2	$1.48M	Buy	15,754 +202	+1%	+$18.6K	0.05%	248
2021 Q1	$1.43M	Buy	15,552 +8,303	+115%	+$701K	0.05%	218
2020 Q4	$530K	Buy	7,249 +693	+11%	+$51.5K	0.02%	428
2020 Q3	$509K	Buy	+6,556	New	+$451K	0.02%	370

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FDx Advisors's HZNP Position: Q2 2023 in Review

FDx Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 5,508 shares — an estimated $627K sold.

FDx Advisors first reported a position in HZNP in Q3 2020 and held it in 11 quarters. The position peaked at $1.74M in Q4 2021. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

FDx Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
FDx Advisors sold 5,508 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $627K.
FDx Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 11 quarters.
FDx Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.74M in Q4 2021.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on FDx Advisors's 13F filing for Q2 2023, filed 17 Jul 2023.